Updates from Syncona and our portfolio companies
London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with Hannover Medical School (MHH). Under the terms of the agreement, Quell Therapeutics will collaborate in joint research with MHH to accelerate the discovery and validation of multiple Chimeric Antigen Receptor (CAR)-Treg cell therapies.
Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the appointment of Carsten Boess as Non-Executive Director to its Board, effective 1 April 2020.
- Experienced clinical leader with extensive experience in guiding rare disease therapies to registration - London, 23 March, 2020 – Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the appointment of Julie Krop M.D., as Chief Medical Officer (CMO) effective 1 April, 2020.
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today provides an update on its business following the outbreak of the COVID-19 pandemic.
Achilles Therapeutics (“Achilles”), a clinical stage oncology company developing personalised cell therapies targeting clonal neoantigens (a novel class of tumour target), today announced the appointment of Professor Sergio Quezada as Chief Scientific Officer (CSO) with effect from 6 April 2020.
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that the European Commission (EC) has granted orphan drug designation for FLT190 for the treatment of Fabry Disease, based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, today announced completion of the acquisition of assets and capabilities from Excellerate Biosciences (“Excellerate”), including a team of experienced pharmacologists led by Professor Steven Charlton.
LONDON, February 25, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the Cowen 40th Annual Health Care Conference in Boston on Wednesday, March 4, 2020 at 10.00 am ET. The company will also host one-on-one meetings with attendees.
LONDON, UK, February 24, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2019 financial results and operational highlights before open of U.S. markets on Tuesday, March 3, 2020.
- Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders - Oxford, 17 February 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, today announced completion of an extended Series A financing of £27.5 million from existing investors Syncona Ltd (“Syncona”) and Oxford Sciences Innovation (“OSI”) who contributed £16.6 million and £10.4 million respectively. They were joined in the round with £0.5 million from the University of Oxford. This comes after an initial Series A investment of £14 million in 2018 bringing the total series A to £41.5 million.